iCorNet develops a tailor-made cardiac support net specifically designed for patients with severe heart failure, particularly those suffering from dilated cardiomyopathy. This technology offers an alternative treatment option beyond medication and heart transplantation, aiming to slow disease progression and enhance patients' quality of life.
Funding
$1.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Dilated cardiomyopathy, a form of severe heart failure, has limited treatment options beyond medication and heart transplantation. These existing treatments may not be suitable or effective for all patients, highlighting the need for alternative solutions to slow disease progression and improve quality of life.
Solution
iCorNet is developing a cardiac support net tailored for individuals with dilated cardiomyopathy. This investigational device is designed to provide external support to the weakened heart, aiming to improve cardiac function and slow the progression of the disease. The support net is intended as an alternative treatment option for patients who may not be eligible for or responsive to traditional therapies. iCorNet collaborates with UT-Heart laboratory to develop durable, seamless support nets customized to each patient's anatomy.
Target Audience
The primary target audience includes patients diagnosed with dilated cardiomyopathy and medical professionals in the field of cardiology.
Features
- Tailor-made design for a precise fit to the individual patient's heart
- Seamless construction to minimize the risk of fraying and ensure long-term durability
- Intended to provide external support to the heart, improving cardiac function